Improving growth in infants with CF

Megan E Gabel1,2, Rachel E Gaudio3, Ala K Shaikhkhalil4,5

  • 1University of Rochester Medical Center, University of Rochester, Rochester, New York, USA.

Pediatric Pulmonology
|August 6, 2024
PubMed

Insights

Cystic fibrosis (CF) infants face growth challenges from birth, impacting health outcomes. Early nutritional support and interdisciplinary care are crucial for improving growth and survival in children with CF.

Area of Science:

  • Pediatric Nutrition
  • Gastroenterology
  • Pulmonology

Background:

  • Cystic fibrosis (CF) is a genetic disorder causing chronic pulmonary and gastrointestinal issues.
  • Malnutrition and poor growth are significant complications of CF, correlating with adverse clinical outcomes.
  • Early diagnosis via newborn screening enables prompt nutritional intervention and clinical management.

Purpose of the Study:

  • To highlight the critical importance of optimizing growth in infants diagnosed with cystic fibrosis.
  • To underscore the challenges and priorities in managing infant growth in CF care.
  • To emphasize the need for a comprehensive, interdisciplinary approach to CF infant management.

Main Methods:

  • Review of current understanding of growth obstacles in infants with CF.
  • Emphasis on the role of early nutritional counseling and clinical follow-up.
  • Highlighting the necessity of integrated care involving registered dietitians and social work.

Main Results:

  • Infants with CF often experience intrauterine growth restriction and lower birth weights.
  • Improved infant growth in CF is demonstrably linked to better clinical outcomes and survival rates.
  • Despite advances, challenges in linear growth, nutrition biomarkers, and health inequities persist.

Conclusions:

  • Optimizing growth is a paramount concern for infants with cystic fibrosis.
  • An interdisciplinary team approach is essential for addressing the complex nutritional and health needs of CF infants.
  • Overcoming barriers like social determinants of health is vital for global CF communities.

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
150
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
201
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
126